SM
KRYS icon

SG3 Management’s Krystal Biotech KRYS Stock Holding History

SG3 Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-22,700
Closed -$1.59M – 1189
2021
Q4 		$1.59M Buy
22,700
+13,200
+139% +$768K 0.03% 380
2021
Q3 		$496K Buy
+9,500
New +$562K 0.02% 600

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SG3 Management's KRYS Position: Q1 2022 in Review

SG3 Management sold out of Krystal Biotech (KRYS) in Q1 2022, closing a stake of 14,879 shares — an estimated $1.04M sold.

SG3 Management first reported a position in KRYS in Q4 2021 and held it in 1 quarter. The position peaked at $1.04M in Q4 2021. 135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

  • SG3 Management reported no remaining Krystal Biotech position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 14,879 Krystal Biotech shares in Q1 2022, an estimated $1.04M.
  • SG3 Management first reported a position in Krystal Biotech in Q4 2021 and held it in 1 quarter.
  • SG3 Management's Krystal Biotech position peaked at $1.04M in Q4 2021.
  • 135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.